/Lilly(Eli)%20%26%20Co%20logo%20on%20building-by%20Michael%20Vi%20via%20Shutterstock.jpg)
Indianapolis, Indiana-based Eli Lilly and Company (LLY) is a pharmaceutical company that discovers, develops, and markets human pharmaceuticals. Valued at a market cap of $735.9 billion, the company is known for its groundbreaking treatments in areas such as diabetes, cancer, neuroscience, and immunology. It is expected to announce its fiscal Q2 earnings for 2025 before the market opens on Thursday, Aug. 7.
Ahead of this event, analysts expect this pharmaceuticals giant to report a profit of $5.55 per share, up 41.6% from $3.92 per share in the year-ago quarter. The company has topped Wall Street’s earnings estimates in two of the last four quarters, while missing on two other occasions. In Q1, LLY’s EPS of $3.34 fell short of the forecasted figure by 5.1%.
For fiscal 2025, analysts expect LLY to report a profit of $21.99 per share, up 69.3% from $12.99 per share in fiscal 2024. Furthermore, its EPS is expected to grow 40% year-over-year to $30.79 in fiscal 2026.

LLY has fallen 10.3% over the past 52 weeks, lagging behind both the S&P 500 Index's ($SPX) 13.4% uptick and the Health Care Select Sector SPDR Fund’s (XLV) 10.2% drop over the same time frame.

On May 1, Shares of Eli Lilly plunged 11.7% after its Q1 earnings release. The company’s revenue surged 45.2% year-over-year to $12.7 billion, surpassing consensus estimates. However, while its adjusted EPS of $3.34 improved 29.5% from the year-ago quarter, it fell short of analyst expectations by 5.1%, which might have weighed down investor sentiment. Additionally, LLY lowered its fiscal 2025 adjusted EPS guidance to a range of $20.78 to $22.28, which may have further dampened investor confidence.
Wall Street analysts are highly optimistic about LLY’s stock, with an overall "Strong Buy" rating. Among 26 analysts covering the stock, 20 recommend "Strong Buy," two indicate "Moderate Buy," and four suggest "Hold.” The mean price target for LLY is $983.46, implying a 26.7% premium from the current levels.